WO2010046035A1 - Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel - Google Patents
Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel Download PDFInfo
- Publication number
- WO2010046035A1 WO2010046035A1 PCT/EP2009/007247 EP2009007247W WO2010046035A1 WO 2010046035 A1 WO2010046035 A1 WO 2010046035A1 EP 2009007247 W EP2009007247 W EP 2009007247W WO 2010046035 A1 WO2010046035 A1 WO 2010046035A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- mmol
- compound
- methyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 150000008059 anilinopyrimidines Chemical class 0.000 title abstract description 5
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 96
- 238000011282 treatment Methods 0.000 claims description 74
- 238000002360 preparation method Methods 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 125000005555 sulfoximide group Chemical group 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 150000003462 sulfoxides Chemical class 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- RGJNPJRAXMSHKN-UHFFFAOYSA-N 2,4-dichloro-5-iodopyrimidine Chemical group ClC1=NC=C(I)C(Cl)=N1 RGJNPJRAXMSHKN-UHFFFAOYSA-N 0.000 claims description 8
- 238000007866 imination reaction Methods 0.000 claims description 8
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical group FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 238000007306 functionalization reaction Methods 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 122
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 74
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 230000004614 tumor growth Effects 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 239000011734 sodium Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 29
- 239000012074 organic phase Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 28
- 239000000543 intermediate Substances 0.000 description 27
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 238000011786 NMRI nude mouse Methods 0.000 description 23
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 208000019065 cervical carcinoma Diseases 0.000 description 17
- 125000004122 cyclic group Chemical group 0.000 description 17
- 0 C*C(*)COc1nc(Nc(cc2)ccc2S(*)(=NC(C(F)(F)F)=O)=O)ncc1C(F)(F)F Chemical compound C*C(*)COc1nc(Nc(cc2)ccc2S(*)(=NC(C(F)(F)F)=O)=O)ncc1C(F)(F)F 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 16
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 16
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- 238000011269 treatment regimen Methods 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229960001456 adenosine triphosphate Drugs 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- -1 2-amino-4-substituted pyrimidines Chemical class 0.000 description 8
- 108091007914 CDKs Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000009422 growth inhibiting effect Effects 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- IJHDUILFGSHIBP-UHFFFAOYSA-N n-[(4-aminophenyl)-methyl-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)N=S(=O)(C)C1=CC=C(N)C=C1 IJHDUILFGSHIBP-UHFFFAOYSA-N 0.000 description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 8
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 7
- QXXLGNAGTMOWEV-RFZPGFLSSA-N (2r,3r)-3-[[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino]butan-2-ol Chemical compound C[C@@H](O)[C@@H](C)NC1=NC(Cl)=NC=C1C(F)(F)F QXXLGNAGTMOWEV-RFZPGFLSSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 6
- GBBKUOJBAQLKJO-UHFFFAOYSA-N n-[(4-aminophenyl)-cyclopropyl-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound C1=CC(N)=CC=C1S(=O)(=NC(=O)C(F)(F)F)C1CC1 GBBKUOJBAQLKJO-UHFFFAOYSA-N 0.000 description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- BICUJNSAYOQPSE-UHFFFAOYSA-N n-[(4-aminophenyl)-ethyl-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)N=S(=O)(CC)C1=CC=C(N)C=C1 BICUJNSAYOQPSE-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- UYHNEJWCEPMJTN-RXMQYKEDSA-N (3r)-3-[[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino]-2-methylbutan-2-ol Chemical compound CC(O)(C)[C@@H](C)NC1=NC(Cl)=NC=C1C(F)(F)F UYHNEJWCEPMJTN-RXMQYKEDSA-N 0.000 description 3
- IEMJDGAUPKXAFK-GHMZBOCLSA-N 2-chloro-4-[(2r,3r)-3-phenylmethoxybutan-2-yl]oxy-5-(trifluoromethyl)pyrimidine Chemical compound O([C@H](C)[C@@H](C)OC=1C(=CN=C(Cl)N=1)C(F)(F)F)CC1=CC=CC=C1 IEMJDGAUPKXAFK-GHMZBOCLSA-N 0.000 description 3
- LBEPQYJTMVBHNQ-GHMZBOCLSA-N 2-chloro-5-iodo-4-[(2r,3r)-3-phenylmethoxybutan-2-yl]oxypyrimidine Chemical compound O([C@H](C)[C@@H](C)OC=1C(=CN=C(Cl)N=1)I)CC1=CC=CC=C1 LBEPQYJTMVBHNQ-GHMZBOCLSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 3
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 3
- 101100327242 Drosophila melanogaster CycE gene Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000012766 Growth delay Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 101100059444 Mus musculus Ccnb1 gene Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 3
- VQEAOBYESZEWRQ-NXEZZACHSA-N (2r,3r)-3-phenylmethoxybutan-2-ol Chemical compound C[C@@H](O)[C@@H](C)OCC1=CC=CC=C1 VQEAOBYESZEWRQ-NXEZZACHSA-N 0.000 description 2
- IDEOPBXRUBNYBN-SCSAIBSYSA-N (3r)-2-methylbutane-2,3-diol Chemical compound C[C@@H](O)C(C)(C)O IDEOPBXRUBNYBN-SCSAIBSYSA-N 0.000 description 2
- AUIQOVDFRCJHSE-RXMQYKEDSA-N (3r)-3-(2-chloro-5-iodopyrimidin-4-yl)oxy-2-methylbutan-2-ol Chemical compound CC(O)(C)[C@@H](C)OC1=NC(Cl)=NC=C1I AUIQOVDFRCJHSE-RXMQYKEDSA-N 0.000 description 2
- GCXULSFFEYTDMA-UHFFFAOYSA-N 1-cyclopropylsulfinyl-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)C1CC1 GCXULSFFEYTDMA-UHFFFAOYSA-N 0.000 description 2
- XXZUBAOBGOBJDT-UHFFFAOYSA-N 1-ethylsulfanyl-4-nitrobenzene Chemical compound CCSC1=CC=C([N+]([O-])=O)C=C1 XXZUBAOBGOBJDT-UHFFFAOYSA-N 0.000 description 2
- AFCWNANLOYZRSC-UHFFFAOYSA-N 1-ethylsulfinyl-4-nitrobenzene Chemical compound CCS(=O)C1=CC=C([N+]([O-])=O)C=C1 AFCWNANLOYZRSC-UHFFFAOYSA-N 0.000 description 2
- HURKDQGMBYYLJO-YSWAMKRWSA-N 2,2,2-trifluoro-n-[[4-[[4-[(2r,3r)-3-hydroxybutan-2-yl]oxy-5-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-methyl-oxo-$l^{6}-sulfanylidene]acetamide Chemical compound C1=C(C(F)(F)F)C(O[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)S(C)(=O)=NC(=O)C(F)(F)F)=N1 HURKDQGMBYYLJO-YSWAMKRWSA-N 0.000 description 2
- GJRQBCHDOKEVSA-NFHXWWKXSA-N 2,2,2-trifluoro-n-[methyl-oxo-[4-[[4-[(2r,3r)-3-phenylmethoxybutan-2-yl]oxy-5-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-$l^{6}-sulfanylidene]acetamide Chemical compound O([C@H](C)[C@@H](C)OC=1C(=CN=C(NC=2C=CC(=CC=2)S(C)(=O)=NC(=O)C(F)(F)F)N=1)C(F)(F)F)CC1=CC=CC=C1 GJRQBCHDOKEVSA-NFHXWWKXSA-N 0.000 description 2
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 2
- LIPLGVYNDCOBIJ-BFHBGLAWSA-N 2-chloro-4-[(2r)-3-methyl-3-(oxan-2-yloxy)butan-2-yl]oxy-5-(trifluoromethyl)pyrimidine Chemical compound O([C@H](C)C(C)(C)OC1OCCCC1)C1=NC(Cl)=NC=C1C(F)(F)F LIPLGVYNDCOBIJ-BFHBGLAWSA-N 0.000 description 2
- PLQWSKKCURONNZ-BFHBGLAWSA-N 2-chloro-5-iodo-4-[(2r)-3-methyl-3-(oxan-2-yloxy)butan-2-yl]oxypyrimidine Chemical compound O([C@H](C)C(C)(C)OC1OCCCC1)C1=NC(Cl)=NC=C1I PLQWSKKCURONNZ-BFHBGLAWSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical group NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 description 2
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- VTONWPRITDCKRC-UHFFFAOYSA-N ethyl-imino-(4-nitrophenyl)-oxo-$l^{6}-sulfane Chemical compound CCS(=N)(=O)C1=CC=C([N+]([O-])=O)C=C1 VTONWPRITDCKRC-UHFFFAOYSA-N 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- OSHPSKAPWFEQST-UHFFFAOYSA-N imino-methyl-(4-nitrophenyl)-oxo-$l^{6}-sulfane Chemical compound CS(=N)(=O)C1=CC=C([N+]([O-])=O)C=C1 OSHPSKAPWFEQST-UHFFFAOYSA-N 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- SBZSIIWCGJHCQN-UHFFFAOYSA-N n-[cyclopropyl-(4-nitrophenyl)-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=NC(=O)C(F)(F)F)C1CC1 SBZSIIWCGJHCQN-UHFFFAOYSA-N 0.000 description 2
- LKMCULOYYJYYIM-NOJNCRTQSA-N n-[cyclopropyl-oxo-[4-[[4-[(2r,3r)-3-phenylmethoxybutan-2-yl]oxy-5-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound O([C@H](C)[C@@H](C)OC=1C(=CN=C(NC=2C=CC(=CC=2)S(=O)(=NC(=O)C(F)(F)F)C2CC2)N=1)C(F)(F)F)CC1=CC=CC=C1 LKMCULOYYJYYIM-NOJNCRTQSA-N 0.000 description 2
- HPTPQDNYPPOREW-UHFFFAOYSA-N n-[ethyl-(4-nitrophenyl)-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)N=S(=O)(CC)C1=CC=C([N+]([O-])=O)C=C1 HPTPQDNYPPOREW-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- VUPQHSHTKBZVML-UHFFFAOYSA-J rhodium(3+);tetraacetate Chemical compound [Rh+3].[Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O VUPQHSHTKBZVML-UHFFFAOYSA-J 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
- KTONHQWVGGOXAH-RFZPGFLSSA-N (2r,3r)-3-(5-bromo-2-chloropyrimidin-4-yl)oxybutan-2-ol Chemical compound C[C@@H](O)[C@@H](C)OC1=NC(Cl)=NC=C1Br KTONHQWVGGOXAH-RFZPGFLSSA-N 0.000 description 1
- RPJFJHRTKAGBEM-WJJGPTJFSA-N (2r,3r)-3-[[2-[4-(methylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]butan-2-ol Chemical compound C1=C(C(F)(F)F)C(N[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)S(C)(=N)=O)=N1 RPJFJHRTKAGBEM-WJJGPTJFSA-N 0.000 description 1
- VREIZDQPOMNWLM-VKKIDBQXSA-N (2r,3r)-3-aminobutan-2-ol;hydrochloride Chemical compound Cl.C[C@@H](N)[C@@H](C)O VREIZDQPOMNWLM-VKKIDBQXSA-N 0.000 description 1
- DAMXCAOOTGBODX-RXMQYKEDSA-N (3r)-3-[(5-bromo-2-chloropyrimidin-4-yl)amino]-2-methylbutan-2-ol Chemical compound CC(O)(C)[C@@H](C)NC1=NC(Cl)=NC=C1Br DAMXCAOOTGBODX-RXMQYKEDSA-N 0.000 description 1
- RYQTYXLOEDUZBQ-LUGWNYHVSA-N (3r)-3-[[5-bromo-2-[4-(cyclopropylsulfonimidoyl)anilino]pyrimidin-4-yl]amino]-2-methylbutan-2-ol Chemical compound C1=C(Br)C(N[C@H](C)C(C)(C)O)=NC(NC=2C=CC(=CC=2)[S@](=N)(=O)C2CC2)=N1 RYQTYXLOEDUZBQ-LUGWNYHVSA-N 0.000 description 1
- RYQTYXLOEDUZBQ-TYUJQUHCSA-N (3r)-3-[[5-bromo-2-[4-(cyclopropylsulfonimidoyl)anilino]pyrimidin-4-yl]amino]-2-methylbutan-2-ol Chemical compound C1=C(Br)C(N[C@H](C)C(C)(C)O)=NC(NC=2C=CC(=CC=2)S(=N)(=O)C2CC2)=N1 RYQTYXLOEDUZBQ-TYUJQUHCSA-N 0.000 description 1
- OVKDLPZRDQTOJW-SCSAIBSYSA-N (3r)-3-amino-2-methylbutan-2-ol Chemical compound C[C@@H](N)C(C)(C)O OVKDLPZRDQTOJW-SCSAIBSYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- OWBTYPJTUOEWEK-QWWZWVQMSA-N (R,R)-butane-2,3-diol Chemical compound C[C@@H](O)[C@@H](C)O OWBTYPJTUOEWEK-QWWZWVQMSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- SPIWTTJEIQYNPK-UHFFFAOYSA-N 1-[[1,3-bis(methylamino)-2,4-dihydropyrimidin-2-yl]oxy]propan-2-ol Chemical class CNN1CC=CN(NC)C1OCC(C)O SPIWTTJEIQYNPK-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- MLTFFVSGGPGNSP-UHFFFAOYSA-N 1-methylsulfinyl-4-nitrobenzene Chemical compound CS(=O)C1=CC=C([N+]([O-])=O)C=C1 MLTFFVSGGPGNSP-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- WUHBHLGDGOQSPG-UHFFFAOYSA-N 2,2,2-trifluoro-n-[methyl-(4-nitrophenyl)-oxo-$l^{6}-sulfanylidene]acetamide Chemical compound FC(F)(F)C(=O)N=S(=O)(C)C1=CC=C([N+]([O-])=O)C=C1 WUHBHLGDGOQSPG-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FCAPSTIZPULFJG-BKVLDKJMSA-N CCS(c(cc1)ccc1Nc1ncc(C(F)(F)F)c(N[C@H](C)C(C)(C)O)n1)(=N)=O Chemical compound CCS(c(cc1)ccc1Nc1ncc(C(F)(F)F)c(N[C@H](C)C(C)(C)O)n1)(=N)=O FCAPSTIZPULFJG-BKVLDKJMSA-N 0.000 description 1
- RUDBFGSCOUUKEY-VQLLWRFMSA-N CCS(c(cc1)ccc1Nc1ncc(C(F)(F)F)c(N[C@H](C)[C@@H](C)O)n1)(=N)=O Chemical compound CCS(c(cc1)ccc1Nc1ncc(C(F)(F)F)c(N[C@H](C)[C@@H](C)O)n1)(=N)=O RUDBFGSCOUUKEY-VQLLWRFMSA-N 0.000 description 1
- LPPPFWQCXCFAAN-FXBGSENESA-N C[C@H]([C@@H](C)Oc1nc(Nc(cc2)ccc2S(C)(=N)=O)ncc1Br)O Chemical compound C[C@H]([C@@H](C)Oc1nc(Nc(cc2)ccc2S(C)(=N)=O)ncc1Br)O LPPPFWQCXCFAAN-FXBGSENESA-N 0.000 description 1
- UELYDGOOJPRWGF-MFOHZAOFSA-N C[C@H]([C@@H](C)Oc1nc(Nc(cc2)ccc2S(C2CC2)(=N)=O)ncc1C(F)(F)F)O Chemical compound C[C@H]([C@@H](C)Oc1nc(Nc(cc2)ccc2S(C2CC2)(=N)=O)ncc1C(F)(F)F)O UELYDGOOJPRWGF-MFOHZAOFSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- OTDGLACDCXIXKG-UHFFFAOYSA-N FC(F)(F)C(=O)S(=N)=O Chemical compound FC(F)(F)C(=O)S(=N)=O OTDGLACDCXIXKG-UHFFFAOYSA-N 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- PQGAHNJECSVDEI-UHFFFAOYSA-N [CH2]CCCCC Chemical compound [CH2]CCCCC PQGAHNJECSVDEI-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- NQUFBBVYXNYYDX-UHFFFAOYSA-N cyclopropanethiol Chemical compound SC1CC1 NQUFBBVYXNYYDX-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- LPEKGGXMPWTOCB-GSVOUGTGSA-N methyl (R)-lactate Chemical compound COC(=O)[C@@H](C)O LPEKGGXMPWTOCB-GSVOUGTGSA-N 0.000 description 1
- VSHMNCDOBJDFHU-GJGWSPMOSA-N n-[cyclopropyl-[4-[[4-[(2r,3r)-3-hydroxybutan-2-yl]oxy-5-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound C1=C(C(F)(F)F)C(O[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)S(=O)(=NC(=O)C(F)(F)F)C2CC2)=N1 VSHMNCDOBJDFHU-GJGWSPMOSA-N 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical class N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
Definitions
- the present invention relates to selected sulfoximinesubsitu Vietnamese ministunasemiconductor (STYPE), their process for the preparation and their use as a medicament for the treatment of various diseases.
- CDK cyclin-dependent kinases
- CDKs Represents molecules.
- Selective inhibitors of CDKs can be used to treat cancers or other diseases that cause cell proliferation disorders.
- Pyrimidines and analogues have already been described as active ingredients such as, for example, the 2-anilino-pyrimidines as fungicides (DE 4029650) or substituted pyrimidine derivatives for the treatment of neurological or neurodegenerative diseases (WO 99/19305).
- CDK inhibitors a wide variety of pyrimidine derivatives are described, for example 2-amino-4-substituted pyrimidines (WO 01/14375), purines (WO 99/02162), 5-cyano-pyrimidines (WO 02/04429), anilinopyrimidines (WO 00 / 12486) and 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines (WO 00/39101).
- WO 02/096888 and WO 03/076437 have disclosed pyrimidine derivatives which have inhibitory effects on CDKs.
- Compounds which contain a phenylsulfonamide group are known as inhibitors of human carbonic anhydrases (in particular carbonic anhydrase-2) and are used as diuretics, inter alia, for the treatment of glaucoma.
- the nitrogen atom and the oxygen atoms of the sulfonamide bind by hydrogen bonding with the zinc 2+ ion and the amino acid Thr 199 in the active center of carbonic anhydrase-2 and thereby block their enzymatic function (A. Casini, F. Abbate, A. Scozzafava, CT. Supuran, Bioorganic, Med. Chem. Lett., 2003, 1, 2759).
- the clinical use of CDK inhibitors containing a phenylsulfonamide group could be limited by the possibility of inhibiting the carbonic anhydrases and a resulting side effect spectrum.
- sulfoximine active substances are sulfonimidoyl-modified triazoles as fungicides (H. Kawanishi, H. Morimoto, T. Nakano, T. Watanabe, K. Oda, K.
- WO 2005/037800 discloses open sulfoximine-substituted anilino-pyrimidine derivatives as inhibitors of cyclin-dependent kinases. Exemplified are structures which are either not substituted in the 5-position of the pyrimidine or substituted with halogen, in particular with bromine. A 5-trifluoromethyl substituent does not have any of the specifically disclosed structures.
- Invention to provide compounds which not only potently inhibit CDK, but which also effectively inhibit tumor growth.
- potent CDK inhibition is a necessary but not sufficient prerequisite for effective tumor inhibition.
- further properties of the structures are necessary, such as the penetration properties into the tumor cell.
- R 1 is a methyl, ethyl, propyl or isopropyl group
- R 2 and R 3 are independently hydrogen, methyl or
- Ethyl group, and R 4 is a CrC 6 alkyl group or a C 3 -C 7 cycloalkyl ring, and their salts, diate isomers and enantiomers, not only inhibit CDK potent, but also inhibit tumor growth particularly effective.
- a C 1 -C 6 -alkyl group is in each case to be understood as meaning a straight-chain or branched alkyl radical, such as, for example, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl or a hexyl radical.
- a C 3 -C 7 cycloalkyl ring is to be understood as meaning a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl ring.
- X may be -O- or -NH-.
- X is -O-.
- R 1 may represent a methyl, ethyl, propyl or isopropyl group.
- R 1 is a methyl group.
- R 2 and R 3 may independently represent hydrogen, a methyl or ethyl group.
- BBeevvoorrzzuuggtt sstteefhen R 2 and R 3 independently represent hydrogen or a methyl group.
- BBeessoonnddeerrss bbee vorzugt 1 R 2 is a methyl group and R 3 represents hydrogen or a methyl group.
- R 4 may be a C 1 -C 6 -alkyl radical or a C 3 -
- R 4 is a methyl or ethyl group or a cyclopropyl ring.
- a preferred subgroup of the compounds according to the general formula (I) are compounds according to general formula (I) in which
- X is -O- or -NH-, and R 1 is a methyl group, and R 2 is a methyl group, and R 3 is hydrogen or a methyl group, and R 4 is a methyl or ethyl group or a cyclopropyl ring , as well as their salts, diatereomers and enantiomers.
- the compounds of the invention are suitable for treatment
- cancer such as solid tumors, tumor metastases, and hematologic tumors, in particular:
- Gastrointestinal tumors such as e.g. Gastric carcinoma, colorectal carcinoma, pancreatic carcinoma,
- Hepatocellular carcinoma Hepatocellular carcinoma; Endokin active tumors; Breast and gynecological tumors; Genitourinary tumors, e.g. Renal cell carcinoma, bladder carcinoma, prostate carcinoma; Tumors of the skin; sarcomas; Leukemias and lymphomas. • of viral diseases, as well
- cardiovascular diseases such as stenosis, arteriosclerosis and restenosis, stent-induced restenosis.
- the formulation of the compounds according to the invention into pharmaceutical preparations is carried out in a manner known per se by converting the active substance (s) into the desired administration form with the auxiliaries customary in galenicals.
- auxiliaries may, for example, vehicles, fillers, disintegrants, binders, humectants, lubricants, adsorbents and agents, diluents, solvents, cosolvents, emulsifiers, solubilizers, flavoring agents, colorants, preservatives, stabilizers, wetting agents, salts for changing the osmotic pressure or buffers are used.
- vehicles fillers, disintegrants, binders, humectants, lubricants, adsorbents and agents, diluents, solvents, cosolvents, emulsifiers, solubilizers, flavoring agents, colorants, preservatives, stabilizers, wetting agents, salts for changing the osmotic pressure or buffers are used.
- Remington 's Pharmaceutical Science 15th ed. Mack Publishing Company, East Pennsylvania (1980).
- the pharmaceutical formulations may be in solid form, for example as tablets, dragees, pills, suppositories, capsules, transdermal systems or in semisolid form, for example as ointments, creams, gels, suppositories, emulsions or in liquid form, for example as solutions, Tinctures, suspensions or emulsions are present.
- auxiliaries for the purposes of the invention may be, for example, salts, saccharides (mono-, di-, tri-, oligo-, and / or polysaccharides), proteins, amino acids, peptides, fats, waxes, oils, hydrocarbons and derivatives thereof, the auxiliaries may be of natural origin or synthetically or partially synthetically obtained.
- Sulfoximines generally have a high stability in terms of structure and configuration (C. Boim, JP Hildebrand, J. Org. Chem. 2000, 65, 169). These properties of the functional group also often allow for drastic reaction conditions and allow the simple derivatization of the sulfoximines on the imine nitrogen and the ⁇ -carbon. Enantiomerically pure sulfoximines are also used as auxiliaries in diastereoselective synthesis ((a) SG Pyne, Sulfur Reports 1992, 12, 57; (b) CR Johnson, Aldrichimica Acta 1985, 18, 3).
- a compound of formula (IVd) is oxidized to the sulfoxide of formula (IVc).
- Many methods, including stereoselective ones, are available for the conversion of a thioether into a sulfoxide (see, for example: (a) M.H. Ali et al., Synthesis 1997, 764. b) M.C. Carreno, Chem. Rev. 1995, 95, 1717; c. I. Patel et al, Org. Proc. Res. Dev.
- reaction of a sulfoxide of the formula (IVc) initially takes place to form an unprotected sulfoximine of the formula (IVb).
- Suitable methods are, for example: a) The reaction of the sulfoxide with sodium azide / conc. Sulfuric acid (see eg: (a) CR Johnson, PE Rogers, J. Org. Chem. 1973, 38, 1793). b) The reaction of the sulfoxide with sodium azide / oleum (see, for example: (a) NV Kondratenko, OA Radchenko, LM Yagupol ' ski, J. Org. Chem. USSR 1984, 20, 2051).
- Process step e) In principle, various methods are available for the replacement of a halogen for a trifluoromethyl group in a nitrogen-containing heteroaromatic radical (see, for example: a) GE Carr, RD Chambers, TF Holmes, J. Chem. Soc. Perkin Trans. 1, 1988, 921; b) F. Cottet, M. Schlosser, Eur. J. Org. Chem. 2002, 327; c) FG Njoroge et al, J.Med.Chem 1997, 40, 4290).
- a 2-chloro-pyrimidine of formula (V) can be reacted with an aniline of formula (IV) to give an intermediate of formula (III) (see, for example: (a) J. Bryant et al, WO 2004/048343).
- Process Step h) The cleavage of the trifluoroaceto group on the sulfoximine (II) yields the compound of the formula (Ia).
- Particularly suitable for this purpose is the described methodology using potassium carbonate in methanol at room temperature (see, for example, (a) H. Okamura, C. Boim, Org. Lett. 2004, 6, 1305).
- Process steps a) -c) These process steps are identical to the process steps a) -d) for the preparation of compounds according to general formula (Ia).
- a 2-chloro-pyrimidine of the formula (Vb) can be reacted with an aniline of the formula (IV) to give an intermediate of the formula (IIb) (see, for example: (a) J. Bryant et al., WO 2004/048343).
- WO 2005/037800 are disclosed or fall under the generic disclosure.
- Example 11 The reference substance in Example 11 is the more active stereoisomer of the diastereomeric mixture (RS) -S- [4 - ( ⁇ 5-bromo-4 - [(R) - (2-hydroxy-1,2-dimethylpropyl) amino] pyrimidine-2 yl ⁇ amino) phenyl] -S-cyclopropyl-sulfoximide, which is disclosed as Example 1.6 in the application WO 2005/037800 (page 35).
- Example 11 the diastereomer was (R) -S- [4 - ( ⁇ 5-bromo-4- [(R) - (2-hydroxy-1,2-dimethylpropyl) amino] pyrimidine-2 -yl ⁇ amino) phenyl] -S-cyclopropylsulfoximide, which has a stronger in vitro effectiveness than (S) -S- [4 - (5-bromo-4 - [(R) - (2-hydroxy-1, 2-dimethylpropyl) amino] pyrimidin-2-yl ⁇ amino) phenyl] -S-cyclopropylsulfoximide.
- V11 was prepared by the following method: V11a) Preparation of the intermediate product
- Example 1.52 has a stronger in vitro effectiveness than Example 1.53.
- Example 13 The comparison substance in Example 13 was prepared according to Example 3.13 of WO 2005/037800.
- Example 3.13 has a stronger in vitro effectiveness than Example 3.12.
- V14 5 Br comparative substance in Example 14
- (2R, 3R) was -3- (5-bromo-2-chloro-pyrimidin-4-yloxy) butan-2-ol and stirring was continued at 80 0 C. After 3 hours, again with 0.75 ml of 4N solution of hydrogen chloride in dioxane and stirred at 80 0 C further. After 33 hours, again with 175 mg (0.60 mmol) (RS) -S- (4-aminophenyl) -S-cyclopropyl-N- (trifluoroacetyl) sulfoximide and stirred finally 18 hours at 80 0 C.
- Stereoisomer 2 showed the greater in vitro effectiveness than stereoisomer 1 and was therefore used as reference in Example 14.
- CDK1 and CycB GST fusion proteins purified from baculovirus-infected insect cells were purchased from ProQinase GmbH, Freiburg.
- the histone MIS used as kinase substrate can be purchased through Sigma.
- CDK1 / CycB 200 ng / measuring point was incubated for 10 min at 22 ° C.
- test substances (0 ⁇ M, as well as within the range 0.01-100 ⁇ M) in assay buffer [50 mM Tris / HCl pH8.0, 10 mM MgCl 2 , 0.1 mM Na ortho-vanadate, 1.0 mM dithiothreitol, 0.5 ⁇ M adenosine trisphosphate (ATP), 10 ⁇ g / measuring point histone HIS, 0.2 ⁇ Ci / measuring point 33 P-gamma ATP, 0, 05% NP40, 1, 25% Dimethyl sulfoxide] incubated. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 ⁇ l / measuring point).
- EDTA solution 250 mM, pH 8.0, 15 ⁇ l / measuring point.
- CDK2 and CycE GST fusion proteins purified from baculovirus-infected insect cells were purchased from ProQinase GmbH, Freiburg. Histone INS, which was used as a kinase substrate, was purchased from Sigma.
- CDK2 / CycE (50 ng / measuring point) was incubated for 10 min at 22 ° C. in the presence of various concentrations of test substances (0 ⁇ M, as well as within the range 0.01-100 ⁇ M) in assay buffer [50 mM Tris / HCl pH8.0, 10 mM MgCl 2 , 0.1 mM Na ortho-vanadate, 1.0 mM dithiothreitol, 0.5 ⁇ M adenosine trisphosphate (ATP), 10 ⁇ g / measurement point histone IHS, 0.2 ⁇ Ci / measurement point 33 P-gamma ATP, 0, 05% NP40, 1.25% dimethylsulfoxide]. The reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 ⁇ l / measuring point).
- Recombinant VEGF receptor tyrosine kinase-2 was purified as a GST fusion protein from baculovirus-infected insect cells (Sf9).
- VEGF receptor tyrosine kinase (90 ng / measuring point) was incubated for 10 min at 22 ° C. in the presence of various concentrations of test substances (0 ⁇ M and within the range 0.001-30 ⁇ M) in 30 ⁇ l assay buffer [40 mM Tris / HCl pH 5.5, 10 mM MgCl 2 , 1 mM MnCl 2 , 3 ⁇ M Na ortho-vanadate, 1, 0 mM dithiothreitol, 8 ⁇ M adenosine trisphosphate (ATP), 0.96 ⁇ g / assay poly (GIU 4 Tyr), 0.2 ⁇ Ci / assay 33 P-gamma ATP, 1.4% dimethylsulfoxide].
- the reaction was stopped by addition of EDTA solution (250 mM, pH 8.0, 15 ⁇ l / measuring point). From each reaction, 15 ⁇ l was applied to P30 filter strips (Wallac) and unincorporated 33 P-ATP was removed by washing the filter strips three times each for 10 minutes in 0.5% phosphoric acid. After drying the filter strip for 1 hour at 70 0 C., the filter strips were (MeltiLexTM A, Fa. Wallac) and for 1 hour at 90 0 C baked with scintillator strips. The amount of incorporated 33 P (substrate phosphorylation) was determined by scintillation measurement in a gamma radiation meter (Wallac). The data were normalized to 0% inhibition (enzyme reaction without inhibitor) and 100% inhibition (all assay components except enzyme). The determination of the IC 50 values was carried out by means of a 4-parameter fit using proprietary software. 10.4 Assay 4: proliferation assay
- the cells were incubated for 4 days in the presence of the test substances. Cell proliferation was determined by staining the cells with crystal violet.
- the cells were fixed by adding 20 ⁇ l / measuring point of an 11% glutaraldehyde solution for 15 minutes at room temperature. After washing the fixed cells three times with water, the plates were dried at room temperature.
- the cells were stained by adding 100 ⁇ l / measuring point of a 0.1% crystal violet solution (pH adjusted to pH3 by addition of acetic acid). After washing the stained cells three times with water, the plates were dried at room temperature.
- the dye was dissolved by adding 100 ⁇ l / measuring point of a 10% acetic acid solution. The extinction was determined photometrically at a wavelength of 595 nm.
- Example 5-SI-2 The in vivo effectiveness of Example 5-SI-2 was compared in Example 11 with V11.
- the in vivo effectiveness of Example 1-SI-2 was compared in Example 14 with V14.
- the in vivo effectiveness of Example 1-SI-2 was compared in Example 14 with V14.
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm 2 .
- Group 1 control, treatment with solubilizer (40% PEG400 / 60% water)
- the study was designed to determine the initial response of a human
- Example 5-SI-2 Cervical carcinoma xenograft model for the therapies with Example 5-SI-2.
- the growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice.
- Example 5-SI-2 was completely dissolved in the solubilizer 40% polyethylene glycol (PEG) 400/60% water to a final concentration of 0.5 mg / ml.
- the treatment of the established tumors was started on day 4 after inoculation of the tumors.
- the study was terminated on day 17 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm 2 .
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm 2 .
- Group 1 Control, treatment with solubilizer (30% HPSSCD / 70% water)
- Group 2 compound according to WO 2005/037800 prepared as disclosed above
- the study was designed to determine the initial response of a human
- Cervical carcinoma xenograft model was designed for the therapies with the 5-Br comparison substance V11.
- the growth-inhibiting effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice.
- V11 was completely dissolved in the solubilizer 30% ⁇ -hydroxypropyl cyclodextrin (HP ⁇ CD) / 70% water to a final concentration of 0.8 mg / ml.
- HP ⁇ CD ⁇ -hydroxypropyl cyclodextrin
- the treatment of the established tumors was started on day 4 after inoculation of the tumors.
- the study was terminated on day 17 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm 2 .
- Example 5-SI-2 (5-CF 3 )
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 150 mm 2 .
- Group 1 Control, treatment with solubilizer (40% PEG 400/60% water)
- Example 6-SI-2 was dissolved in the solubilizer 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.3 mg / ml (Group 2), 0.4 mg / ml (Group 3), or 0.5 mg / ml (Group 4) completely dissolved.
- PEG 400 polyethylene glycol 400
- Example 6-SI-2 inhibits tumor growth in the HeLa-MaTu xenograft model dose-dependently in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days.
- Group 1 Control, treatment with solubilizer (40% PEG 400/60% water)
- the study was designed to determine the initial response of a human cervical carcinoma xenograft model to the 5-Br comparator V12 therapies.
- the growth-inhibiting effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice.
- V12 in the solubilizer was added to 40% polyethylene glycol 400 (PEG 400) / 60% water a final concentration of 0.7 mg / ml (Group 2), 0.85 mg / ml (Group 3), or 1.0 mg / ml (Group 4) completely dissolved.
- the treatment of the established tumors was started on day 4 after inoculation of the tumors.
- the study was terminated on day 28 after the tumor size of the animals of group 1 (control) exceeded the size of about 150 mm 2 .
- Example 6-SI-2 (5-CF 3 )
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm 2 .
- Group 1 Control, treatment with solubilizer (40% PEG 400/60% water)
- Example 2-SI-2 in the solubilizer was 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.15 mg / ml (Group 2), 0.2 mg / ml (Group 3), or 0.25 mg / ml (Group 4) completely solved.
- the treatment of the established tumors was started on day 5 after inoculation of the tumors.
- Example 2-SI-2 inhibits tumor growth in the HeLa-MaTu xenograft model dose-dependently in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days.
- T / C 0.18, p ⁇ 0.05.
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm 2 .
- Group 1 Control, treatment with solubilizer (40% PEG 400/60% water)
- the study was designed to determine the initial response of a human cervical carcinoma xenograft model to the therapies with the
- V13 5 Br comparison substance designed.
- the growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice.
- V13 was completely solubilized in the solubilizer 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.6 mg / ml (Group 2), 0.8 mg / ml (Group 3), or 1.0 mg / ml (Group 4) solved.
- PEG 400 polyethylene glycol 400
- Example 2-SI-2 (5-CF 3 )
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were subcutaneously inserted into the flank of female NMRI
- Nude mice implanted Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 .
- the study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm 2 .
- Group 1 Control, treatment with solubilizer (40% PEG 400/60% water)
- Example 1-SI-2 in the solubilizer was 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.15 mg / ml (Group 2), 0.2 mg / ml (Group 3), or 0.25 mg / ml (Group 4) completely solved.
- PEG 400 polyethylene glycol 400
- Example 1-SI-2 inhibits tumor growth in the HeLa-MaTu xenograft model dose-dependently in a treatment regimen consisting of two daily oral applications on 2 consecutive days followed by 5 treatment-free days.
- T / C 0.19, p ⁇ 0.05.
- HeLa-MaTu human cervical carcinoma cells cultured in cell culture were implanted subcutaneously into the flank of female NMRI nude mice. Treatment was started as soon as the tumors had grown to a size of about 20 mm 2 . The study was terminated as soon as the tumors in one of the groups reached a size of approx. 160 mm 2 .
- Group 1 Control, treatment with solubilizer (40% PEG 400/60% water)
- Group 2 Compound according to WO 2005/037800 prepared as described above V14 (6 mg / kg, orally, twice a day 5, 6, 12, 13, 19, 20)
- Group 3 compound according to WO 2005/037800 prepared as disclosed above
- the study was designed to determine the initial response of a human cervical carcinoma xenograft model to the 5-Br comparator V14 therapies.
- the growth inhibitory effect of the compounds was tested in the HeLa-MaTu Cervixtumor model as xenograft on NMRI nude mice.
- V14 was completed in the solubilizer 40% polyethylene glycol 400 (PEG 400) / 60% water to a final concentration of 0.6 mg / ml (Group 2), 0.8 mg / ml (Group 3), or 1.0 mg / ml (Group 4) solved.
- the treatment of the established tumors was started on day 5 after inoculation of the tumors.
- Example 1-SI-2 (5-CF 3 )
- Example 1-SI-2 5-CF 3
- Fig. 1 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 5-SI-2.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0.
- Treatment started on day 4 after the tumors had reached a size of about 20 mm 2 .
- Treatments were performed in the following dosages and application regimens:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water)
- group 2 example 5-SI-2, cyclic treatment scheme
- Fig. 2 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V11.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0.
- Treatment started on day 4 after the tumors had reached a size of about 20 mm 2 .
- the treatments were carried out in the following dosages and application schemes:
- Group 1 (control group) - solubilizer (30% HPSSCD / 70% water,
- Group 2 V11, cyclic treatment scheme
- FIG. 3 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 6-SI-2.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0.
- Treatment started on day 4 after the tumors had reached a size of about 20 mm 2 .
- the treatments were given in following dosages and in a cyclic
- Treatment regimen consisting of two daily oral applications performed on days 4, 5, 11, 12, 17, and 18:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water);
- Group 2 Example 6-SI-2, dosage 3 mg / kg;
- Fig. 4 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V12.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0.
- Treatment started on day 4 after the tumors had reached a size of about 20 mm 2 .
- the treatments were performed in the following dosages and in a cyclic regimen consisting of two daily oral applications on days 4, 5, 11, 12, 17, 18, 23 and 24:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water);
- Group 2 V12, dosage 7 mg / kg;
- Group 3 V12, dosage 8.5 mg / kg; Group 4: V12, dosage 10 mg / kg.
- Fig. 5 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 2-SI-2.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm 2 . The treatments were given in following dosages and in a cyclic
- Treatment schedule consisting of two daily oral applications performed on days 5, 6, 12, 13, 19, and 20:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water);
- Group 2 Example 2-SI-2, dosage 1.5 mg / kg;
- Group 3 Example 2-SI-2, dosage 2 mg / kg;
- Group 4 Example 2-SI-2, dosage 2.5 mg / kg.
- Fig. 6 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V13.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm 2 . The treatments were performed in the following dosages and in a cyclic regimen consisting of two daily oral applications on days 5, 6, 12, 13, 19, and 20:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water); Group 2: V13, dosage 6 mg / kg; Group 3: V13, dosage 8 mg / kg; Group 4: V13, dosage 10 mg / kg.
- Fig. 7 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with Example 1-SI-2.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm 2 . The treatments were given in following dosages and in a cyclic
- Treatment schedule consisting of two daily oral applications performed on days 5, 6, 12, 13, 19, and 20:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water);
- Group 2 Example 1-SI-2, dosage 1.5 mg / kg;
- Group 3 Example 1-SI-2, dosage 2 mg / kg;
- Group 4 Example 1-SI-2, dosage 2.5 mg / kg.
- FIG. 8 shows the tumor growth inhibition in the human HeLa-MaTu Cervixtumor xenograft model under treatment with V14.
- HeLa-MaTu cells were subcutaneously implanted into NMRI nude mice on day 0. The treatment started on day 5 after the tumors had reached a size of about 20 mm 2 . The treatments were performed in the following dosages and in a cyclic regimen consisting of two daily oral applications on days 5, 6, 12, 13, 19, and 20:
- Group 1 (control group) - solubilizer (40% PEG400 / 60% water); Group 2: V14, dosage 6 mg / kg; Group 3: V14, dosage 8 mg / kg; Group 4: V14, dosage 10 mg / kg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL09778874T PL2350026T3 (pl) | 2008-10-21 | 2009-10-09 | Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek |
CA2739739A CA2739739C (en) | 2008-10-21 | 2009-10-09 | Sulfoximine-substituted anilino-pyrimidine derivatives as cdk inhibitors, production and use thereof as medicinal products |
MX2011004238A MX2011004238A (es) | 2008-10-21 | 2009-10-09 | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales. |
RSP20140466 RS53523B1 (en) | 2008-10-21 | 2009-10-09 | ANILINE-PYRIMIDINE DERIVATIVES WITH SUBSTITUTED SULFOXIMIN AS CDK INHIBITORS, THEIR PRODUCTION AND USE AS MEDICINES |
BRPI0920112A BRPI0920112A2 (pt) | 2008-10-21 | 2009-10-09 | derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento. |
DK09778874.9T DK2350026T3 (da) | 2008-10-21 | 2009-10-09 | Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel |
CN200980141978.7A CN102197029B (zh) | 2008-10-21 | 2009-10-09 | 作为cdk抑制剂的亚砜亚胺取代的苯胺基嘧啶衍生物、其制备以及作为药物的用途 |
ES09778874.9T ES2499028T3 (es) | 2008-10-21 | 2009-10-09 | Derivados de anilino-pirimidina sustituidos con sulfoximina como inhibidores de CDK, su preparación y uso como medicamentos |
NZ592314A NZ592314A (en) | 2008-10-21 | 2009-10-09 | Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine |
AU2009306733A AU2009306733C1 (en) | 2008-10-21 | 2009-10-09 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine |
UAA201106183A UA103500C2 (uk) | 2008-10-21 | 2009-10-09 | Сульфоксимінзаміщені анілінопіримідинові похідні як cdk-інгібітори, їх одержання й застосування як лікарських засобів |
EA201100623A EA019230B1 (ru) | 2008-10-21 | 2009-10-09 | Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств |
EP09778874.9A EP2350026B1 (de) | 2008-10-21 | 2009-10-09 | Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel |
US13/125,066 US8735412B2 (en) | 2008-10-21 | 2009-10-09 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine |
JP2011532519A JP5564054B2 (ja) | 2008-10-21 | 2009-10-09 | Cdkインヒビターとしてのスルホキシミン−置換されたアニリノ−ピリミジン誘導体類、それらの製造及び医薬製剤としてのそれらの使用 |
SI200931004T SI2350026T1 (sl) | 2008-10-21 | 2009-10-09 | S sulfoksiminom substituirani derivati anilin pirimidina, kot inhibitorji CDK, njihova izdelava in uporaba kot zdravilo |
IL211713A IL211713A (en) | 2008-10-21 | 2011-03-14 | History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs |
CU2011000088A CU24052B1 (es) | 2008-10-21 | 2011-04-20 | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos |
TN2011000199A TN2011000199A1 (en) | 2008-10-21 | 2011-04-20 | Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine |
MA33786A MA32723B1 (fr) | 2008-10-21 | 2011-04-20 | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments |
ZA2011/03727A ZA201103727B (en) | 2008-10-21 | 2011-05-20 | Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine |
HRP20140830AT HRP20140830T1 (hr) | 2008-10-21 | 2014-09-03 | Sulfoksimin supstituirani derivati anilin pirimidina kao inhibitori cdk, njihova proizvodnja i uporaba kao lijeka |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08167113.3 | 2008-10-21 | ||
EP08167113A EP2179991A1 (de) | 2008-10-21 | 2008-10-21 | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010046035A1 true WO2010046035A1 (de) | 2010-04-29 |
Family
ID=40282208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/007247 WO2010046035A1 (de) | 2008-10-21 | 2009-10-09 | Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel |
Country Status (38)
Country | Link |
---|---|
US (1) | US8735412B2 (de) |
EP (2) | EP2179991A1 (de) |
JP (1) | JP5564054B2 (de) |
KR (1) | KR20110069115A (de) |
CN (1) | CN102197029B (de) |
AR (1) | AR074053A1 (de) |
AU (1) | AU2009306733C1 (de) |
BR (1) | BRPI0920112A2 (de) |
CA (1) | CA2739739C (de) |
CO (1) | CO6361926A2 (de) |
CR (1) | CR20110210A (de) |
CU (1) | CU24052B1 (de) |
CY (1) | CY1115590T1 (de) |
DK (1) | DK2350026T3 (de) |
DO (1) | DOP2011000107A (de) |
EA (1) | EA019230B1 (de) |
EC (1) | ECSP11010992A (de) |
ES (1) | ES2499028T3 (de) |
HN (1) | HN2011001019A (de) |
HR (1) | HRP20140830T1 (de) |
IL (1) | IL211713A (de) |
MA (1) | MA32723B1 (de) |
MX (1) | MX2011004238A (de) |
MY (1) | MY155230A (de) |
NZ (1) | NZ592314A (de) |
PA (1) | PA8846201A1 (de) |
PE (1) | PE20110546A1 (de) |
PL (1) | PL2350026T3 (de) |
PT (1) | PT2350026E (de) |
RS (1) | RS53523B1 (de) |
SA (1) | SA109300632B1 (de) |
SI (1) | SI2350026T1 (de) |
TN (1) | TN2011000199A1 (de) |
TW (2) | TWI458716B (de) |
UA (1) | UA103500C2 (de) |
UY (1) | UY32190A (de) |
WO (1) | WO2010046035A1 (de) |
ZA (1) | ZA201103727B (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
WO2011018518A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives |
DE102010014426A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
WO2012038411A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von pan-cdk-inhibitoren der formel (i), sowie intermediate der herstellung |
DE102011080992A1 (de) | 2011-08-16 | 2013-02-21 | Bayer Pharma AG | Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren |
WO2013024118A1 (de) | 2011-08-16 | 2013-02-21 | Bayer Intellectual Property Gmbh | Verwendung von ccne2 als stratifikationsmarker bei der behandlung von brusttumoren mit neuen pan-cdk-inhibitoren |
JP2015510910A (ja) * | 2012-03-21 | 2015-04-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 特定の腫瘍の処置のための、(rs)−s−シクロプロピル−s−(4−{[4−{[(1r,2r)−2−ヒドロキシ−1−メチルプロピル]オキシ}−5−(トリフルオロメチル)ピリミジン−2−イル]アミノ}フェニル)スルホキシミドの使用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
EP2755948B1 (de) | 2011-09-16 | 2016-05-25 | Bayer Intellectual Property GmbH | Disubstituierte 5-fluor-pyrimidinderivate mit einer sulfoximingruppe |
EP3207038B1 (de) * | 2014-10-16 | 2018-08-22 | Bayer Pharma Aktiengesellschaft | Fluorierte benzofuranyl-pyrimidin-derivate mit einer sulfoximingruppe |
CA3111977A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037800A1 (de) * | 2003-10-16 | 2005-04-28 | Schering Aktiengesellschaft | Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel |
WO2007071455A1 (en) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine-substituted pyrimidines , their preparation and use as drugs |
WO2007140957A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Aktiengesellschaft | Sulfimide als proteinkinaseinhibitoren |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
ES2253821T3 (es) | 1997-07-12 | 2006-06-01 | Cancer Research Technology Limited | Derivados de purina inhibidores de quinasa que depende de ciclina. |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
DE69932828T2 (de) | 1998-08-29 | 2007-10-18 | Astrazeneca Ab | Pyrimidine verbindungen |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
AU2002312933B2 (en) | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
JP2005526765A (ja) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
EP1794134A1 (de) * | 2004-09-29 | 2007-06-13 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2008
- 2008-10-21 EP EP08167113A patent/EP2179991A1/de not_active Withdrawn
-
2009
- 2009-10-09 WO PCT/EP2009/007247 patent/WO2010046035A1/de active Application Filing
- 2009-10-09 ES ES09778874.9T patent/ES2499028T3/es active Active
- 2009-10-09 MX MX2011004238A patent/MX2011004238A/es active IP Right Grant
- 2009-10-09 MY MYPI2011001632A patent/MY155230A/en unknown
- 2009-10-09 CA CA2739739A patent/CA2739739C/en not_active Expired - Fee Related
- 2009-10-09 DK DK09778874.9T patent/DK2350026T3/da active
- 2009-10-09 KR KR1020117009024A patent/KR20110069115A/ko active IP Right Grant
- 2009-10-09 NZ NZ592314A patent/NZ592314A/xx not_active IP Right Cessation
- 2009-10-09 AU AU2009306733A patent/AU2009306733C1/en not_active Ceased
- 2009-10-09 UA UAA201106183A patent/UA103500C2/uk unknown
- 2009-10-09 SI SI200931004T patent/SI2350026T1/sl unknown
- 2009-10-09 CN CN200980141978.7A patent/CN102197029B/zh not_active Expired - Fee Related
- 2009-10-09 RS RSP20140466 patent/RS53523B1/en unknown
- 2009-10-09 EA EA201100623A patent/EA019230B1/ru not_active IP Right Cessation
- 2009-10-09 JP JP2011532519A patent/JP5564054B2/ja not_active Expired - Fee Related
- 2009-10-09 BR BRPI0920112A patent/BRPI0920112A2/pt not_active IP Right Cessation
- 2009-10-09 PL PL09778874T patent/PL2350026T3/pl unknown
- 2009-10-09 EP EP09778874.9A patent/EP2350026B1/de active Active
- 2009-10-09 PT PT97788749T patent/PT2350026E/pt unknown
- 2009-10-09 PE PE2011000917A patent/PE20110546A1/es not_active Application Discontinuation
- 2009-10-09 US US13/125,066 patent/US8735412B2/en not_active Expired - Fee Related
- 2009-10-19 PA PA20098846201A patent/PA8846201A1/es unknown
- 2009-10-20 UY UY0001032190A patent/UY32190A/es not_active Application Discontinuation
- 2009-10-20 SA SA109300632A patent/SA109300632B1/ar unknown
- 2009-10-21 AR ARP090104043A patent/AR074053A1/es not_active Application Discontinuation
- 2009-10-21 TW TW098135674A patent/TWI458716B/zh not_active IP Right Cessation
- 2009-10-21 TW TW103126302A patent/TWI496774B/zh not_active IP Right Cessation
-
2011
- 2011-03-14 IL IL211713A patent/IL211713A/en not_active IP Right Cessation
- 2011-04-15 HN HN2011001019A patent/HN2011001019A/es unknown
- 2011-04-20 DO DO2011000107A patent/DOP2011000107A/es unknown
- 2011-04-20 CU CU2011000088A patent/CU24052B1/es active IP Right Grant
- 2011-04-20 EC EC2011010992A patent/ECSP11010992A/es unknown
- 2011-04-20 CO CO11049624A patent/CO6361926A2/es active IP Right Grant
- 2011-04-20 MA MA33786A patent/MA32723B1/fr unknown
- 2011-04-20 TN TN2011000199A patent/TN2011000199A1/fr unknown
- 2011-04-25 CR CR20110210A patent/CR20110210A/es unknown
- 2011-05-20 ZA ZA2011/03727A patent/ZA201103727B/en unknown
-
2014
- 2014-09-03 HR HRP20140830AT patent/HRP20140830T1/hr unknown
- 2014-09-05 CY CY20141100717T patent/CY1115590T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037800A1 (de) * | 2003-10-16 | 2005-04-28 | Schering Aktiengesellschaft | Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel |
WO2007071455A1 (en) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine-substituted pyrimidines , their preparation and use as drugs |
WO2007140957A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Aktiengesellschaft | Sulfimide als proteinkinaseinhibitoren |
Non-Patent Citations (1)
Title |
---|
VERMA S ET AL: "Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 8, 15 April 2005 (2005-04-15), pages 1973 - 1977, XP025314402, ISSN: 0960-894X, [retrieved on 20050415] * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
WO2011018518A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives |
DE102010014426A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
CN103119026A (zh) * | 2010-09-23 | 2013-05-22 | 拜耳知识产权有限责任公司 | 式(I)的pan-CDK抑制剂的制备方法和此制备方法中的中间体 |
DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
US9359306B2 (en) * | 2010-09-23 | 2016-06-07 | Bayer Intellectual Property Gmbh | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation |
RU2585621C2 (ru) * | 2010-09-23 | 2016-05-27 | Байер Интеллектуэль Проперти Гмбх | СПОСОБ ПОЛУЧЕНИЯ пан-ЦЗК-ИНГИБИТОРОВ ФОРМУЛЫ (I), А ТАКЖЕ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ |
CN103119026B (zh) * | 2010-09-23 | 2015-08-19 | 拜耳知识产权有限责任公司 | 式(I)的pan-CDK抑制剂的制备方法和此制备方法中的中间体 |
AU2011304365B2 (en) * | 2010-09-23 | 2015-02-05 | Bayer Intellectual Property Gmbh | Process for preparing pan-CDK inhibitors of the formula (l), and intermediates in the preparation |
WO2012038411A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von pan-cdk-inhibitoren der formel (i), sowie intermediate der herstellung |
US20130245261A1 (en) * | 2010-09-23 | 2013-09-19 | Bayer Intellectual Property Gmbh | Process for preparing pan-cdk inhibitors of the formula (i), and intermediates in the preparation |
JP2013542189A (ja) * | 2010-09-23 | 2013-11-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 式(I)のpan−CDK阻害剤の調製のための方法、および該調製における中間体 |
CN103732763A (zh) * | 2011-08-16 | 2014-04-16 | 拜耳知识产权有限责任公司 | MAD2L2在用新pan-CDK抑制剂治疗乳腺肿瘤中作为分类标志物的用途 |
US20140200233A1 (en) * | 2011-08-16 | 2014-07-17 | Bayer Intellectual Property Gmbh | Use of mad2l2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors |
US20140221243A1 (en) * | 2011-08-16 | 2014-08-07 | Bayer Intellectual Property Gmbh | Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors |
JP2014524250A (ja) * | 2011-08-16 | 2014-09-22 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規のパンcdk阻害剤での***腫瘍の処置における、階層化マーカーとしてのccne2の使用 |
JP2014524249A (ja) * | 2011-08-16 | 2014-09-22 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規のパンcdk阻害剤での***腫瘍の処置における、階層化マーカーとしてのmad2l2の使用 |
WO2013024116A1 (de) | 2011-08-16 | 2013-02-21 | Bayer Intellectual Property Gmbh | Verwendung von mad2l2 als stratifikationsmarker bei der behandlung von brusttumoren mit neuen pan-cdk-inhibitoren |
DE102011080991A1 (de) | 2011-08-16 | 2013-02-21 | Bayer Pharma AG | Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren |
WO2013024118A1 (de) | 2011-08-16 | 2013-02-21 | Bayer Intellectual Property Gmbh | Verwendung von ccne2 als stratifikationsmarker bei der behandlung von brusttumoren mit neuen pan-cdk-inhibitoren |
DE102011080992A1 (de) | 2011-08-16 | 2013-02-21 | Bayer Pharma AG | Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren |
JP2015510910A (ja) * | 2012-03-21 | 2015-04-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 特定の腫瘍の処置のための、(rs)−s−シクロプロピル−s−(4−{[4−{[(1r,2r)−2−ヒドロキシ−1−メチルプロピル]オキシ}−5−(トリフルオロメチル)ピリミジン−2−イル]アミノ}フェニル)スルホキシミドの使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2350026B1 (de) | Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel | |
EP2342185B1 (de) | Sulfonsubstituierte anlinopyrimidinderivative als cdk-inhibitoren, deren herstellung und verwendung als arzneimittel | |
WO2005037800A1 (de) | Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel | |
DD292250A5 (de) | Pharmakologisch aktive, auf das zentralnervensystem wirkende verbindungen | |
US20110294826A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
EP2029552A1 (de) | Sulfimide als proteinkinaseinhibitoren | |
EP1794134A1 (de) | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel | |
WO2007079982A1 (de) | (2 , 4 , 9-triaza-1 (2 , 4 ) -pyrimidina-3 ( 1 , 3 ) -benzenacyclononaphan-3 4-yl) -sulfoximin derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs | |
SK278444B6 (en) | Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its | |
EP1644339B1 (de) | 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren | |
DE102009015070A1 (de) | Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel | |
DE102009001438A1 (de) | Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel | |
DE60018301T2 (de) | Neue pyrimidin-2,4,6-trion-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten | |
DE102004022672A1 (de) | Substituierte Azachinazoline | |
EP1917244A2 (de) | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
EP1286973A2 (de) | Neue carbamate und harnstoffe, ihre herstellung und verwendung als endothelin-rezeptorantagonisten | |
CZ324199A3 (cs) | Léčivo k zabránění růstu solidního tumoru u člověka a způsob jeho výroby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980141978.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09778874 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009778874 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2739739 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009306733 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 592314 Country of ref document: NZ Ref document number: 12011500773 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2011000280 Country of ref document: DZ |
|
ENP | Entry into the national phase |
Ref document number: 20117009024 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011000895 Country of ref document: CL Ref document number: 2011532519 Country of ref document: JP Ref document number: 11049624 Country of ref document: CO Ref document number: D2011088 Country of ref document: CU Ref document number: 000917-2011 Country of ref document: PE Ref document number: MX/A/2011/004238 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 0128911 Country of ref document: KE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2957/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000210 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201100623 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2009306733 Country of ref document: AU Date of ref document: 20091009 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201106183 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13125066 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0466 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: PI0920112 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110420 |